Nasal flu vaccine trials achieve 85% efficacy neutralizing influenza strains for high-risk groups, Health Affairs November 4.
Injection-free immunity promises broader pediatric adoption, reducing clinic burdens 40% via Bluetooth app integration.
CDC interim estimates 60% effective against hospitalization, 50% outpatient for 2025-26 trivalent formula.
University of Hong Kong’s intranasal H5N1 vaccine protects clade 2.3.4.4b in small animal models, April 8, 2025.
ACIP recommends FluMist for ages 2-49, live attenuated influenza vaccine starting mucosal immunity.
98 pediatric deaths last season underscore urgency, nasal’s quiet momentum yields flu’s enduring idyll.
This success’s quiet protection unveils new era where nasal’s vast spray bridges injection voids, transforming immunity with enduring harmony.
